4-(5-(3-tert-butyl-5-isopropylphenyl)-1-(4-(methylsulfonyl)phenyl)-1H-pyrazol-3-yl)benzoic acid

ID: ALA3813965

Chembl Id: CHEMBL3813965

PubChem CID: 127048322

Max Phase: Preclinical

Molecular Formula: C30H32N2O4S

Molecular Weight: 516.66

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)nn2-c2ccc(S(C)(=O)=O)cc2)cc(C(C)(C)C)c1

Standard InChI:  InChI=1S/C30H32N2O4S/c1-19(2)22-15-23(17-24(16-22)30(3,4)5)28-18-27(20-7-9-21(10-8-20)29(33)34)31-32(28)25-11-13-26(14-12-25)37(6,35)36/h7-19H,1-6H3,(H,33,34)

Standard InChI Key:  IZUIATOTLFSJAY-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA3813965

    ---

Associated Targets(Human)

RARG Tclin Retinoic acid receptor RXR-alpha/gamma (11 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
RARB Tclin Retinoic acid receptor RXR-alpha/Retinoic acid receptor beta (11 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
RARA Tclin Retinoic acid receptor alpha/Retinoid X receptor alpha (28 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 516.66Molecular Weight (Monoisotopic): 516.2083AlogP: 6.73#Rotatable Bonds: 6
Polar Surface Area: 89.26Molecular Species: ACIDHBA: 5HBD: 1
#RO5 Violations: 2HBA (Lipinski): 6HBD (Lipinski): 1#RO5 Violations (Lipinski): 2
CX Acidic pKa: 3.90CX Basic pKa: 1.43CX LogP: 6.95CX LogD: 3.73
Aromatic Rings: 4Heavy Atoms: 37QED Weighted: 0.31Np Likeness Score: -1.17

References

1. Hughes NE, Bleisch TJ, Jones SA, Richardson TI, Doti RA, Wang Y, Stout SL, Durst GL, Chambers MG, Oskins JL, Lin C, Adams LA, Page TJ, Barr RJ, Zink RW, Osborne H, Montrose-Rafizadeh C, Norman BH..  (2016)  Identification of potent and selective retinoic acid receptor gamma (RARγ) antagonists for the treatment of osteoarthritis pain using structure based drug design.,  26  (14): [PMID:27261179] [10.1016/j.bmcl.2016.05.056]

Source